날짜	액션	분석자	등급 변경
2023-12-13	재개	Citigroup	Neutral
2023-12-12	개시	Deutsche Bank	Buy
2023-10-24	재개	Cantor Fitzgerald	Overweight
2023-08-21	재확인	Mizuho	Neutral
2023-07-24	업그레이드	SVB Securities	Market Perform → Outperform
2023-07-06	업그레이드	BMO Capital Markets	Underperform → Market Perform
2023-05-04	업그레이드	Guggenheim	Neutral → Buy
2023-03-30	업그레이드	Canaccord Genuity	Hold → Buy
2023-03-03	업그레이드	Evercore ISI	In-line → Outperform
2023-02-03	업그레이드	Morgan Stanley	Equal-Weight → Overweight
2022-11-14	다운그레이드	Evercore ISI	Outperform → In-line
2022-10-11	개시	UBS	Buy
2022-09-26	개시	Wells Fargo	Equal Weight
2022-06-06	재개	Jefferies	Buy
2022-03-03	다운그레이드	Piper Sandler	Overweight → Neutral
2022-02-25	업그레이드	Goldman	Neutral → Buy
2022-01-18	다운그레이드	RBC Capital Mkts	Outperform → Sector Perform
2021-11-19	개시	BMO Capital Markets	Underperform
2021-11-17	업그레이드	JP Morgan	Neutral → Overweight
2021-10-14	다운그레이드	Morgan Stanley	Overweight → Equal-Weight
2021-09-23	재개	Needham	Hold
2021-08-06	다운그레이드	Canaccord Genuity	Buy → Hold
2021-05-18	재개	Goldman	Neutral
2021-05-06	업그레이드	Barclays	Equal Weight → Overweight
2021-02-02	개시	Raymond James	Outperform
2020-09-30	개시	The Benchmark Company	Hold
2020-08-04	다운그레이드	JP Morgan	Overweight → Neutral
2020-06-29	다운그레이드	Goldman	Buy → Neutral
2020-06-09	개시	Wedbush	Outperform
2020-03-06	개시	Citigroup	Buy
2020-02-27	개시	Barclays	Equal Weight
2020-02-24	개시	William Blair	Outperform
2020-02-06	개시	Mizuho	Neutral
2020-02-05	재확인	H.C. Wainwright	Buy
2019-12-13	다운그레이드	Credit Suisse	Outperform → Neutral
2019-08-07	개시	RBC Capital Mkts	Outperform
2019-07-16	개시	Oppenheimer	Outperform
2019-06-05	개시	Guggenheim	Neutral
2019-05-21	개시	Credit Suisse	Outperform
2019-04-22	업그레이드	JP Morgan	Neutral → Overweight
2019-04-12	개시	Evercore ISI	Outperform
2019-02-06	재확인	BofA/Merrill	Buy
2019-01-23	다운그레이드	JP Morgan	Overweight → Neutral
2018-12-13	개시	Goldman	Buy
2018-11-21	개시	Canaccord Genuity	Buy

내부자 거래	관계	날짜	거래	비용	#주식	가치 ($)	#주식 총계
BENEVICH ERIC	Chief Commercial Officer	Apr 15 '24	Option Exercise	81.21	19,818	1,609,431	53,365
BENEVICH ERIC	Chief Commercial Officer	Apr 15 '24	Sale	133.36	19,818	2,643,020	40,778
Delaet Ingrid	Chief Regulatory Officer	Apr 01 '24	Option Exercise	79.02	272	21,493	7,779
Delaet Ingrid	Chief Regulatory Officer	Apr 01 '24	Sale	137.30	272	37,346	7,507
Delaet Ingrid	Chief Regulatory Officer	Mar 21 '24	Option Exercise	103.52	5,000	517,600	12,507
Delaet Ingrid	Chief Regulatory Officer	Mar 21 '24	Sale	145.06	5,000	725,320	7,507
BENEVICH ERIC	Chief Commercial Officer	Mar 14 '24	Option Exercise	80.90	75,000	6,067,628	110,299
MORROW GEORGE J	Director	Mar 14 '24	Option Exercise	39.79	40,000	1,591,600	20,000
BENEVICH ERIC	Chief Commercial Officer	Mar 14 '24	Sale	139.38	75,000	10,453,417	40,778
MORROW GEORGE J	Director	Mar 14 '24	Sale	139.42	40,000	5,576,710	0

뉴로크린 바이오사이언시스 (NBIX)

뉴로크린 바이오사이언시스 Stock (NBIX) Company Profile

뉴로크린 바이오사이언시스 Stock (NBIX) Upgrades & Downgrades

뉴로크린 바이오사이언시스 주식(NBIX)의 최신 뉴스

Zoetis (ZTS) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Neurocrine Biosciences (NBIX) Reports Next Week: Wall Street Expects Earnings Growth

Where Neurocrine Biosciences Stands With Analysts

Analyst Bullish On Gene Therapy-Focused Voyager Therapeutics Sees Best In Class Potential For Its Neurogenetic Medicine Platform

In-Depth Examination Of 8 Analyst Recommendations For Neurocrine Biosciences

Decoding 8 Analyst Evaluations For Neurocrine Biosciences

뉴로크린 바이오사이언시스 (NBIX) 재무 분석

뉴로크린 바이오사이언시스 (NBIX) 매출 2024

뉴로크린 바이오사이언시스 (NBIX) 순이익 2024

뉴로크린 바이오사이언시스 (NBIX) 현금흐름 2024

뉴로크린 바이오사이언시스 (NBIX) 주당 순이익 2024

뉴로크린 바이오사이언시스 주식 (NBIX) 내부자 거래

NBIX과 유사한 종목